MARKET

OPT

OPT

Opthea Ltd
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.73
+0.32
+4.32%
After Hours: 7.72 -0.01 -0.13% 17:17 07/23 EDT
OPEN
7.75
PREV CLOSE
7.41
HIGH
7.88
LOW
7.65
VOLUME
23.76K
TURNOVER
--
52 WEEK HIGH
17.86
52 WEEK LOW
7.09
MARKET CAP
331.96M
P/E (TTM)
-8.3208
1D
5D
1M
3M
1Y
5Y
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Benzinga · 07/08 16:37
Why Odonate Therapeutics, Opthea, ALX Oncology, Advaxis and Provention Bio Are Moving Today
Odonate Therapeutics, Inc. (NASDAQ: ODT), Opthea Limited (NASDAQ: OPT), ALX Oncology Holdings Inc.
Benzinga · 07/06 14:16
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Benzinga · 07/06 12:07
Opthea’s OPT-302 nabs Fast Track tag in U.S. for wet AMD
Opthea (OPT) announces that the FDA has granted Fast Track designation for its VEGF-C/-D ‘trap’ inhibitor, OPT-302, in combination with anti-VEGF-A therapy for the treatment of patients with neovascular (wet)
Seekingalpha · 07/06 11:35
BRIEF-Opthea’s Opt-302 Granted FDA Fast Track Designation For Wet Age-Related Macular Degeneration
reuters.com · 07/06 11:18
Opthea's OPT-302 Granted FDA Fast Track Designation for Wet Age-Related Macular Degeneration
Opthea Limited ((ASX:OPT, NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, is pleased to announce that the U.S. Food and Drug
Benzinga · 07/06 11:05
Opthea Wins FDA Fast Track Designation for Wet Age-Related Macular Degeneration Treatment
MT Newswires · 07/06 07:51
The Daily Biotech Pulse: Gemini Sinks On Data, Amgen's Migraine Drug Approved In Japan, Liver Congress Gets Underway
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 22)
Benzinga · 06/23 11:35
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of OPT. Analyze the recent business situations of Opthea Ltd through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average OPT stock price target is 35.94 with a high estimate of 47.26 and a low estimate of 24.62.
EPS
Institutional Holdings
Institutions: 8
Institutional Holdings: 5.65M
% Owned: 13.15%
Shares Outstanding: 42.94M
TypeInstitutionsShares
Increased
1
9.15K
New
1
1.50K
Decreased
2
59.39K
Sold Out
4
258.61K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
No Data
About OPT
Opthea Limited, formerly Circadian Technologies Limited, is engaged in developing and commercializing therapies primarily for eye diseases. The Company operates in medical technology and healthcare industry in Australia. The Company is involved in the development activities, which are based on the intellectual property portfolio covering key targets, such as vascular endothelial growth factors [VEGF]-C, -D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, including angiogenesis and lymph angiogenesis respectively, as well as vascular leakage. It is developing its lead molecule, which is a soluble form of VEGFR-3 referred to as OPT-302, for the treatment of wet age-related macular degeneration (wet AMD). OPT-302 blocks two members of the vascular endothelial growth factor family, VEGF-C and VEGF-D, which cause blood vessels to grow and leak. It is investigating OPT-302 in an ongoing Phase I/IIA clinical trial in wet AMD patients.

Webull offers kinds of Opthea Ltd stock information, including NASDAQ:OPT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OPT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading OPT stock methods without spending real money on the virtual paper trading platform.